Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

Biogen (NASDAQ:BIIB – Free Report) had its price objective decreased by Mizuho from $251.00 to $207.00 in a research note published on Thursday,Benzinga reports. Mizuho currently has an outperform ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Biogen (NASDAQ:BIIB) shares rose 1.8% in early New York trading on Wednesday after the company reported third-quarter results that topped analyst expectations. Earnings per share... Investing.com ...

Biogen Pharmachem Industries Limited is an India-based company, which is not engaged in any activity. The Company is looking for the right opportunity to make the Company operational. What is the ...

The volume of shares traded was 1.62 million exceeding the average volume of 1.27 million. In recent trading, Biogen Inc (BIIB) stock price has shown some volatility, fluctuating -5.91% over the last ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

What is the outlook of the S&P 500 index and why top ETFs like the SPY, VOO, and SPY will reverse in the coming weeks.

Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

Investors seemed unconvinced, with Biogen shares dipping 2% after the NEJM publication ... even if it launches with a high price. Biogen is currently squeezed between competitive pressures to ...